{
    "relation": [
        [
            "",
            "Number of Participants [units: participants]",
            "Age, Customized [units: years] Median (Full Range)",
            "Gender [units: participants]",
            "Female",
            "Male",
            "Race (NIH/OMB) [units: participants]",
            "American Indian or Alaska Native",
            "Asian",
            "Native Hawaiian or Other Pacific Islander",
            "Black or African American",
            "White",
            "More than one race",
            "Unknown or Not Reported",
            "Eastern Cooperative Oncology Group Performance Status [1] [units: participants]",
            "0",
            "1",
            "2",
            "3-5",
            "ALK Status [2] [units: participants]",
            "Positive",
            "Negative"
        ],
        [
            "Brentuximab Vedotin",
            "58",
            "52.0 (14 to 76)",
            "",
            "25",
            "33",
            "",
            "0",
            "1",
            "0",
            "7",
            "48",
            "0",
            "2",
            "",
            "19",
            "38",
            "1",
            "0",
            "",
            "16",
            "42"
        ]
    ],
    "pageTitle": "A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00866047?show_locs=Y",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 10,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988308.23/warc/CC-MAIN-20150728002308-00064-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 866453363,
    "recordOffset": 866440835,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Treatment Period Participant Flow for 2 periods Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion Brentuximab Vedotin Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Enrollment period: Jun 2009 - May 2010 Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: brentuximab vedotin Intervention: Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Conditions:",
    "textAfterTable": "\u00a0 Baseline Characteristics \u00a0 Hide Baseline Characteristics Population Description Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate. No text entered. Reporting Groups \u00a0 Description Brentuximab Vedotin Brentuximab vedotin 1.8 mg/kg every 3 weeks by IV infusion Baseline Measures \u00a0 \u00a0 Brentuximab Vedotin \u00a0 Number of Participants \u00a0 [units:\u00a0participants] \u00a0 58 \u00a0 Age, Customized \u00a0 [units:\u00a0years] Median (Full Range) \u00a0 52.0 \u00a0 (14\u00a0to\u00a076) \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}